MAPT and Mental deterioration: Since brain MRI is part of the standard care of progressive cognitive decline, biomarkers measurable on routinely acquired clinical MR images that track pathological changes could supplement the extant invasive (cerebrospinal fluid analysis), logistically challenging and expensive (e.g., amyloid or tau positron emission tomography [PET]), or yet to be clinically validated blood‐based biomarkers (Jack et al., 2010, 2012; Knopman et al., 2001; Li et al., 2022; Zetterberg & Bendlin, 2021).